Graduated i2n Company Finds Success
Fibrocell, an Exton based cell and gene therapy company will be acquired for $63.3M. It became a participating i2n company in 2012 taking advantage of the many network offerings that helped it grow. The company received a total of $100,171 in Keystone Innovation Zone (KIZ) tax credits as an i2n company.
The cell and gene therapy company will become a privately held subsidiary of Castle Creek Pharmaceutical Holdings when the deal closes in the fourth quarter of the year.
Castle Creek Pharmaceutical Holdings will acquire the Exton-based company, which focuses on transformational autologous (that is, obtained from the same individual) cell-based therapies for skin and connective tissue diseases, and the deal is slated to be finalized by the end of the year, a release said.
Read the article in Technical.ly Philly.